Dry AMD Therapeutics Summit | Virtual Conference | 28-29 October 2020

Memo

Finding new therapeutics to counter the progression of Dry AMD and prevent the geographical atrophy has never been more important. The aging population creates an ever-growing clinical need for next-generation therapeutics. This action-packed two-day agenda holds 22 Presentations from industry and academic leaders, a virtual poster session and 5+ hours of networking, you can join the only platform discussing issues present in the development of Dry AMD therapeutics. Join this critical global forum which will again be uniting industry specialists from pharma, biotechs, academia and solution providers as we target the most pressing issues important to bringing the next generation of Dry AMD drugs to market. Prices:Pharma and Biotech Pricing - early birds available : USD 2599.0Academic Pricing - early birds available : USD 1559.0Solution Provider Pricing - early birds available : USD 2499.0 Speakers: Eleonora Lad | Associate Professor of Ophthalmology, Director of Grading Duke Reading Center | Duke University, Gabrielle DeBartolomeo | Clinical Trial Scientist | Alkeus Pharmaceuticals, Leonide Saad | President and CEO | Alkeus Pharmaceuticals, Inc., Lukas Scheibler | Chief Innovation Officer | Apellis Pharmaceuticals, Mark Shearman | Chief Scientific Officer | Applied Genetic Technologies Corporation, Dang Dao | Director - Research | Astellas Pharma Inc, Victor Chong | Global Head of Medicine, Retinal Health | Boehringer Ingelheim International GmbH, Konstantin Petruhkin | Associate Professor | Columbia University, Catherine Bowes Rickman | Professor of Ophthalmology | Duke University, Christopher Brittain | Vice President and Global Head of Ophthalmology Product Development | Genentech, Kourous Rezaei | Chief Medical Officer | IVERIC Bio, Brian M. Culley | Chief Executive Officer | Lineage Cell Therapeutics, Inc, Jeffrey Stern | co-Chief Executive Officer | Neural Stem Cell Institute and Luxa Biotechnology, Kapil Bharti | Senior Investigator | National Institutes of Health, Qian Huang | Head of Ocular Inflammation, Ophthalmology | Novartis, Stephen Poor | Director and Head of Retinal Pharmacology Unit and Imaging Technologies Team | Novartis, Jeffrey S. Heier | CO-President and Medical Director | Ophthalmic Consultants of Boston, Joshua Dunaief | Adele Niessen Professor of Ophthalmology | Scheie Eye Institute University of Pennsylvania, Lloyd Diamond | Chief Executive Officer | Pixium Vision, Jane S. Lebkowski | President Regenerative | Patch Technologies, Karl G. Csaky T. Boone Pickens | Director, Clinical Center of Innovation for AMD, Chief Executive and Medical Officer | Retina Foundation of the Southwest, Reenie McCarthy | Director President and Chief Executive Officer Stealth | BioTherapeutics Inc, Jacque Duncan | Retinal Specialist | University of California, San Francisco, Amir Kashani | Associate Professor of Ophthalmology (Clinical Scholar) | University of Southern California, David Schaffer | Co-Founder, Chief Scientific Officer and Co-Chairman of The Board of Directors | 4D Molecular Therapeutics, Ulrich Luhmann | Biomarker Experimental Medicine Leader, Early Clinical Development | Roche, Irene Wang | Chief Operating Officer | Belite Bio Time: 9:00 am - 4:50 pm